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assembled 78 treatment plans, that they were generated, 36 
IMAT, 18 3DCRT, 3 IMRT, 9 helical irradiation and 12 robotic 
radiosurgery. All gathered data were finally imported into 
one treatment planning system for evaluating different 
planning strategies. 
 
Results: In all plans, the dosimetric coverage of the target 
volume and the dose to OARs were within clinical limits. The 
coverage of the PTV were disclosed: CICRU =1.0(0.9-1.1); 
CI65 =0.7(0.4-1.0); HI=0.3(-0.3-0.5); Dmin/Dmax=0.6(0.5-
0.7); D2%,=64.6(47.5-71.3)Gy; D98%=47.2(39.5-68.6)Gy; 
Dmiddle=57.8(47.3-65.8)Gy. 
In the 3DCRT Plans, the mean dose in the PTV was on 
average, 3 Gy higher than dynamic techniques; MU and 
irradiation time were by the factor of 2-3 higher in the 
dynamic techniques. Dose to the OARs for the 1st and 2nd 
patient is as bellows: Dmedi, ipsilat. lung = 4.9 (3.2-8.8)Gy; 
Dmax, esophagus =7.7(0.4-16.1)Gy. V35Gy, rips =10(0.6-
43.7). For the 3rd one: Dmedi., ipsilat. lung = 8.3(6.8-10)Gy; 
Dmedi.,contralat. lung = 2.3(1.4-4.7)Gy Dmax, 
esophagus=20.7(11.3-27.7)Gy. 
Picture shows the Dmax for the spinal cord. 
 
 
 
Conclusion: All irradiation techniques were applicable for 
clinical use, the resulting dose distribution were quite 
similar. By comparison, the statistically significant 
differences between the users were greater than the 
differences between the techniques. This demonstrate that 
strict constrains and works like the DEGRO reference paper 
(Guckenberger et al) are necessary to homogenize the SBRT 
planning at a national level. 
This study reports the results of the irradiation planning for 
the treatment of NSCLC with SBRT depends largely on the 
user. 
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Purpose or Objective: Management of pelvic sidewall 
recurrence in gynaecological cancers is a challenging clinical 
scenario. Sciatic nerve involvement may exclude surgery and 
cause intractable symptoms that are difficult to palliate. In 
the context of re-irradiation, high doses of radiation without 
consideration of the sciatic nerve can cause irreversible 
nerve damage, yet this has not traditionally been included as 
an OAR.  
The aims of this study were to develop dose target 
constraints for re-irradiation of the sciatic nerve, and to 
assess the impact of nerve-sparing optimisation on target 
volume coverage and OAR sparing with stereotactic 
radiotherapy techniques. 
 
Material and Methods: Cumulative dose constraints for re-
irradiation were derived assuming prior pelvic radiotherapy 
of 50Gy (EQD2) and allowing nerve recovery values of 50% 
and 100%. Treatment plans were produced for 10 patients 
with recurrent gynaecological cancer delivering 30 Gy in 5 
fractions. Two normalisation methods were assessed: ICRU 83 
type normalisation and prescription (ICRU); and stereotactic 
radiosurgery convention of prescribing to the isodose 
covering 95% PTV allowing maximum doses of ~125% (SRS). 
For each method, plans were optimised with and without 
sciatic nerve sparing targets. Sciatic nerve roots were 
contoured from sacral foramina until the nerve exits the 
pelvis. Nerve sparing plans were optimised to minimize dose 
to nerve PRV while maintaining PTV coverage. Doses to GTV, 
PTV, OAR and sciatic nerve were compared. 
 
Results: All 40 plans met the PTV targets with >95% PTV 
coverage by the specified isodose. The sciatic nerve was 
involved in 3 patients, close proximity (<5 mm) in 4 patients 
and more than 5 mm distant from PTV in 3 patients. The dose 
targets were Dmax 32 Gy when there was nerve involvement 
and 21.9 Gy when the nerve was distant from tumour. For all 
patients, the sciatic nerve dose was reduced with each 
technique: median Dmax with ICRU from 28.8 Gy to 22.3 GY 
and with SRS from 28.7 Gy to 19.9 Gy. For patients with overt 
nerve involvement, median Dmax was reduced from 34.9 Gy 
to 32.1 Gy with SRS. Nerve sparing was achieved without 
significantly decreasing GTV mean doses or increasing bowel 
doses.  
 
Conclusion: The sciatic nerve should be an OAR for re-
irradiation of sidewall recurrence. Optimisation using a 
sciatic nerve PRV can significantly reduce dose to nerve by up 
40% (EQD2-2) while having minimal effect on GTV coverage or 
bowel doses. Feasible dose targets depend on proximity of 
nerve to GTV and clinical scenario.  
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Purpose or Objective: Over the last half century we have 
seen remarkable improvements in the survival of pediatric 
cancer patients. Therefore, the impact of cancer and its 
treatment must be assessed. Furthermore, the radiotherapy 
technique must be well selected in order to minimize the 
secondary effects. Since hearing loss is a common late effect 
of radiotherapy, the purpose of this study was to compare 
three different treatment techniques and to evaluate the 
dose to the cochleas and supretentorial brain, in children 
treated with radiotherapy for medulloblastoma.  
 
Material and Methods: A total of 121 children were treated 
in our department with radiotherapy for CNS tumors, 
between January 2000 and December 2014. Those who were 
diagnosed with medulloblastoma were included. A total of 29 
children fulfilled these criteria. The adopted treatment plan 
consisted of a first phase with three-dimensional conformal 
radiotherapy (3D-CRT) to the craniospinal region (prescribed 
doses from 23.4 to 36.0 Gy) followed with a boost to the PTV 
(posterior fossa/tumor bed) with prescribed doses of 18.0 or 
31.6 Gy depending on the clinical risk-group, high or standard 
risk respectively . For each child, three different treatment 
plans were prepared for the boost phase: one with 
conventional 2 parallel opposed fields (CRT), one more 
complex with 3D conformal radiotherapy (3D-CRT) and 
